The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

References

1. 1.↵
   1. Nichols E,
   2. Szoeke CE,
   3. Vollset SE,
   4. Abbasi N,
   5. Abd-Allah F,
   6. Abdela J

   , GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 88–106.

   OpenUrl
2. 2.↵
   1. El-Metwally A,
   2. Toivola P,
   3. Al-Rashidi M,
   4. Nooruddin S,
   5. Jawed M,
   6. AlKanhal R, et al.

   Epidemiology of Alzheimer’s Disease and Dementia in Arab Countries: A Systematic Review. Behav Neurol 2019; 2019: e3935943.
3. 3.
   1. Albugami M,
   2. Qadi N,
   3. Almugbel F,
   4. Mohammed A,
   5. Alttas A,
   6. Elamin A, et al.

   The Demographic Characteristics and the Risk Factors of Dementia in SAUDI Elderly. Am J Psychiatry Neurosci 2018; 6: 1–8.
4. 4.↵
   1. Alsebayel FM,
   2. Alangari AM,
   3. Almubarak FH,
   4. Alhamwy R.

   Prevalence of Dementia and Its Associated Risk Factors Among Geriatric Patients Visiting Primary Healthcare Centers in Riyadh, Saudi Arabia: A Cross-Sectional Study. Cureus 2022; 14: e24394.
5. 5.↵
   Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 2022; 18: 700–789.
6. 6.↵
   1. Velandia PP,
   2. Miller-Petrie MK,
   3. Chen C,
   4. Chakrabarti S,
   5. Chapin A,
   6. Hay S, et al.

   Global and regional spending on dementia care from 2000-2019 and expected future health spending scenarios from 2020-2050: An economic modelling exercise. EClinicalMedicine 2022; 45: 101337.
7. 7.↵
   1. Tayeb HO,
   2. Yang HD,
   3. Price BH,
   4. Tarazi FI.

   Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012; 134: 8–25.
8. 8.↵
   Biogen. Combined FDA and Applicant PCNS Dru sgs Advisory Committee Briefing Document. Published November 6, 2020. Accessed October 16, 2022. https://www.fda.gov/media/143502/download
9. 9.↵
   1. Tagliavini F,
   2. Tiraboschi P,
   3. Federico A.

   Alzheimer’s disease: the controversial approval of Aducanumab. Neurol Sci 2021; 42: 3069–3070.
10. 10.↵
    1. DiStefano MJ,
    2. Alexander GC,
    3. Polsky D,
    4. Anderson GF.

    Public opinion regarding US Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey. J Am Geriatr Soc 2022; 70: 1685–1694.
11. 11.↵
    1. Lythgoe MP,
    2. Jenei K,
    3. Prasad V.

    Regulatory decisions diverge over aducanumab for Alzheimer’s disease. BMJ 2022; 376: e069780.
12. 12.↵
    UAE second country globally to grant approval for first and only drug for treatment of early stages of Alzheimer’s disease. Published March 10, 2021. Accessed October 17, 2022. https://www.wam.ae/en/details/1395302976448
13. 13.↵
    1. Van Dyck CH,
    2. Swanson CJ,
    3. Aisen P,
    4. Bateman RJ,
    5. Chen C,
    6. Gee M, et al.

    Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023; 388: 9–21.
14. 14.↵
    1. Tayeb HO,
    2. Murray ED,
    3. Price BH,
    4. Tarazi FI.

    Bapineuzumab and solanezumab for Alzheimer’s disease: is the “amyloid cascade hypothesis” still alive? Expert Opin Biol Ther 2013; 13: 1075–1084.
15. 15.↵
    1. Day GS,
    2. Scarmeas N,
    3. Dubinsky R,
    4. Coerver K,
    5. Mostacero A,
    6. West B, et al.

    Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee. Neurology 2022; 98: 619–631.
16. 16.↵
    1. Salloway S,
    2. Chalkias S,
    3. Barkhof F,
    4. Burkett P,
    5. Barakos J,
    6. Purcell D, et al.

    Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol 2022; 79: 13–21.
17. 17.↵
    1. Salloway S,
    2. Chalkias S,
    3. Barkhof F,
    4. Burkett P,
    5. Barakos J,
    6. Purcell D, et al.

    A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 2021; 13: 80.
18. 18.↵
    1. Mintun MA,
    2. Lo AC,
    3. Evans CD,
    4. Wessels AM,
    5. Ardayfio PA,
    6. Andersen SW, et al.

    Donanemab in Early Alzheimer’s Disease. N Engl J Med 2021; 384: 1691–1704.
19. 19.↵
    1. Shcherbinin S,
    2. Evans CD,
    3. Lu M,
    4. Andersen SW,
    5. Pontecorvo MJ,
    6. Willis BA, et al.

    Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol 2022; 79: 1015–1024.
20. 20.↵
    1. Zimmer J,
    2. Solomon P,
    3. Evans CD,
    4. Lu M,
    5. Sims JR,
    6. Brooks DA, et al.

    TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (P18-3.005). Neurology 2022; 98: 1688.
21. 21.↵
    Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease. Roche Press Release November 14, 2022. https://www.roche.com/media/releases/med-cor-2022-11-14
22. 22.↵
    1. Andrews JC,
    2. Desai U,
    3. Kirson NY,
    4. Zichlin ML,
    5. Ball DE,
    6. Matthews BR.

    Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement (N Y) 2019; 5: 354–363.
23. 23.↵
    1. Arenaza-Urquijo EM,
    2. Bejanin A,
    3. Gonneaud J,
    4. Wirth M,
    5. La Joie R,
    6. Mutlu J, et al.

    Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation. Neurobiol Aging 2017; 59: 72–79.
24. 24.↵
    1. Noroozian M,
    2. Shakiba A,
    3. Iran-nejad S.

    The impact of illiteracy on the assessment of cognition and dementia: a critical issue in the developing countries. Int Psychogeriatr 2014; 26: 2051–2060.
25. 25.↵
    1. Alshammari SA,
    2. Alhamdan AA,
    3. Bindawas SM,
    4. Al-Amoud MM,
    5. Al-Orf SM,
    6. Al-Muammar MN, et al.

    Assessing the cognitive status of older adults attending primary healthcare centers in Saudi Arabia using the Mini-Mental State Examination. Saudi Med J 2020; 41: 1315–1323.
26. 26.
    1. Muayqil TA,
    2. Alamri NK,
    3. Alqahtani AM,
    4. Julaidan SS,
    5. Alsuhaibani R,
    6. Nafisah I, et al.

    Normative and Equated Data of the Original and Basic Versions of the Montreal Cognitive Assessment among Community Dwelling Saudi Arabians. Behav Neurol 2021; 2021: e5395627.
27. 27.
    1. Alkeridy WA,
    2. Muayqil TA,
    3. Al Khalifah RA,
    4. Mohammedin AS,
    5. Khallaf RA,
    6. Bucks RS.

    Arabic translation and cross-cultural adaptation of the Bristol Activities of Daily Living Scale (BADLS). Alzheimers Dement 2021; 17: e050856.
28. 28.↵
    1. Feghali Y,
    2. Fares Y,
    3. Abou Abbas L.

    Assessment of neuropsychiatric symptoms in dementia: validity and reliability of the Lebanese version of the neuropsychiatric inventory questionnaire. Appl Neuropsychol Adult 2021; 28: 588–595.
29. 29.↵
    1. Alobaidy A,
    2. Al-Sinawi H,
    3. Al-Asmi A,
    4. Al-Adawi S,
    5. Essa MM,
    6. El-Okl M, et al.

    CERAD Neuropsychological Battery-Arabic Version: Regression-Based and Stratified Normative Data and Effects of Demographic Variables on Cognitive Performance in Older Omanis. Cogn Behav Neurol Off J Soc Behav Cogn Neurol 2017; 30: 150–158.
30. 30.↵
    1. Karam GE,
    2. Khandakji MN,
    3. Sahakian NS,
    4. Dandan JC,
    5. Karam EG.

    Validation into Arabic versions of Dementia Rating Scales, Dementia Caregivers Scales, and Dementia Research Instruments. Alzheimers Dement Amst Neth 2018; 10: 796–801.
31. 31.↵
    1. Ben Jemaa S,
    2. Attia Romdhane N,
    3. Bahri-Mrabet A,
    4. Jendli A,
    5. Le Gall D,
    6. Bellaj T.

    An Arabic Version of the Cognitive Subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data. J Alzheimers Dis 2017; 60: 11–21.
32. 32.↵
    1. Aisen P

    1. Apostolova LG

    1. Atri A

    1. Salloway S

    1. Weiner M.

    1. Cummings J

    , Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis 2021; 8: 398–410.

    OpenUrl
33. 33.↵
    1. Schindler SE,
    2. Bollinger JG,
    3. Ovod V,
    4. Mawuenyega KG,
    5. Li Y,
    6. Gordon BA, et al.

    High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019; 93: e1647–e1659.
34. 34.↵
    1. Sinha P,
    2. Barocas JA.

    Cost-effectiveness of aducanumab to prevent Alzheimer’s disease progression at current list price. Alzheimers Dement (N Y) 2022; 8: e12256.
35. 35.↵
    1. Lam J,
    2. Hlávka J,
    3. Mattke S.

    The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey. J Am Board Fam Med 2019; 32: 931–940.
36. 36.↵
    1. Hampel H,
    2. Au R,
    3. Mattke S,
    4. Van der Flier WM.

    Designing the next-generation clinical care pathway for Alzheimer’s disease. Nat Aging 2022; 2: 692–703.